StockNews.com started coverage on shares of Invitae (NYSE:NVTA – Get Free Report) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the medical research company’s stock. Separately, The Goldman Sachs Group cut their target price on Invitae from $1.00 to $0.50 and set a “sell” rating for the […]
From Chinese regulator s new restrictions and Bank of Japan s plans to shift gears to Invitae s bankruptcy woes and Novartis mega acquisition bid,here s a look at some of the major developments from across the world.
StockNews.com began coverage on shares of Invitae (NYSE:NVTA – Free Report) in a research report report published on Friday morning. The brokerage issued a hold rating on the medical research company’s stock. Separately, The Goldman Sachs Group decreased their price objective on Invitae from $1.00 to $0.50 and set a sell rating for the company […]
Strs Ohio lifted its stake in Invitae Co. (NYSE:NVTA – Free Report) by 46.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 569,800 shares of the medical research company’s stock after buying an additional 181,800 shares during the period. Strs Ohio […]